Comments
Hetero has received manufacturing and marketing approval for the investigational antiviral medicine remdesivir from the Drug Controller General of India (DCGI) for the treatment of Covid-19.
It is launching the generic version of remdesivir under the ‘Covifor’ brand in India.
“Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country,” said Hetero Chairman B Partha Saradhi Reddy in a release issued here on Sunday.
“We are prepared for ensuring enough stocks required to cater to the present needs. We will continue to work closely with the government and medical community to make a difference in the fight against Covid-19,” he added.
The product is made indigenously in line with the ‘Make in India’ campaign, he added.
Remdesivir has been granted approval by the DCGI for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children hospitalised with severe symptoms of the disease.
Covifor will be available in 100 mg vials (injectable) which have to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.
The product is launched under a licensing agreement with Gilead Sciences Inc to expand access to Covid-19 treatment in low and middle-income countries.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.